{"data":{"id":300,"lang":"en","title":"Surgeons Implant Lab-Grown Dopamine Cells Into Parkinson Patients Brains in FDA Fast-Tracked Trial","summary":"USC surgeons implant lab-grown dopamine cells into Parkinson patients brains in FDA fast-tracked trial with 12 participants across three US sites.","category":"science","category_label":"Science","published_at":"2026-02-20T22:02:18Z","updated_at":"2026-02-20T22:02:18Z","url":"https://techtools.cz/tools/news/article/300-surgeons-implant-lab-grown-dopamine-cells-into-parkinson-patients-brains-in-fda","api_url":"https://techtools.cz/news-api/v1/articles/300?lang=en","markdown_url":"https://techtools.cz/news-api/v1/articles/300.md?lang=en","image_url":"https://content.presspage.com/uploads/2478/a45182d3-d62d-4ac4-8a8b-b9e2395e775b/1920_adobestock_1490818895.jpeg?10000","word_count":178,"reading_time_minutes":1,"sources":[{"url":"https://news.keckmedicine.org/new-stem-cell-treatment-may-offer-hope-for-parkinsons-disease/","domain":"news.keckmedicine.org"},{"url":"https://www.sciencedaily.com/releases/2026/02/260219040820.htm","domain":"sciencedaily.com"},{"url":"https://medicalxpress.com/news/2026-02-stem-cell-brain-implants-aim.html","domain":"medicalxpress.com"}],"translation":{"lang":"cs","id":283,"title":"Chirurgové implantují laboratorně vypěstované dopaminové buňky do mozků pacientů s Parkinsonovou chorobou v zrychlené studii FDA","url":"https://techtools.cz/tools/news/clanek/283-chirurgove-implantuji-laboratorne-vypestovane-dopaminove-bunky-do-mozku","api_url":"https://techtools.cz/news-api/v1/articles/283?lang=cs"},"content":"Surgeons at Keck Medicine of USC have begun implanting lab-grown dopamine-producing cells directly into the brains of Parkinson's disease patients in a first-of-its-kind clinical trial. The therapy, called RNDP-001 and developed by Kenai Therapeutics, uses induced pluripotent stem cells — adult cells reprogrammed into a versatile state capable of becoming dopamine neurons. Surgeons create a small skull opening and use MRI guidance to place the cells into the basal ganglia, the brain region controlling movement.\n\nThe Phase 1 REPLACE trial has enrolled 12 participants with moderate to severe Parkinson's across three U.S. sites. The FDA granted the trial fast-track designation to accelerate development. Patients will be monitored for 12 to 15 months initially, with follow-up extending up to five years.\n\nNo existing treatment can stop or slow Parkinson's progression — current drugs only manage symptoms. If the implanted cells successfully restore dopamine production, it could fundamentally change how the disease is treated. Principal investigator Dr. Brian Lee said the goal is for the brain to once again produce normal levels of dopamine, potentially slowing the disease and restoring motor function."}}